Small molecule-based PD-1 pathway blockade for Human cancer therapy: NQO1 (NAD(P)H dehydrogenase [quinone] ) inhibits the expression of co-inhibitory receptor PD-1 on Antigen- Specific T-cells, increases the production of cytokines by tumor-infiltrating lymphocytes (TIL), and draining lymph nodes and augments anti-tumor activity via down-regulation of its target gene, 21/December/2016, 11.30 pm

Molecular therapy for Myocardial Infarction: Lithium, the widely used drug in the treatment of depressive/bipolar disorders, inhibits DNA damage responses, increases telomerase expression, inhibits telomere shortening, and promotes cardiomyocyte survival after myocardial infarction via up-regulation of PNUTS, 21/December/2016, 11.07 pm
December 21, 2016
Natural product-derived PD-L1 pathway blockade enhances the efficacy of Cancer immunotherapy: Withaferin A, a lactone isolated from herb Withania Somnifera/Ashwagandha and Acnistus arborescens, inhibits the expression of PD-L1, inhibits inflammatory signalling and the number of tumor-infiltrating lymphocytes and macrophages, increases Cytotoxic activity of T-cells, decreases tumor burden and increases survival via up-regulation of its target gene, 22/December/2016, 8.29 pm
December 22, 2016
Show all

Introduction:What they say:

A recent study from Division of Infectious Diseases, School of Medicine, Johns Hopkins University, Baltimore, MD 21218, United States shows that “TGF-β1-Mediated Smad3 Enhances PD-1 Expression on Antigen-Specific T Cells in Cancer.” This study was published in the 28 September 2016 issue of Cancer Discovery (one of the best journals in Cancer Science with an impact factor of 19+) by Prof Andrea L. Cox, Park BV and others.


What we say

On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Small molecule-based PD-1 pathway blockade for Human cancer therapy:NQO1 (NAD(P)H dehydrogenase [quinone]) inhibits the expression of co-inhibitory receptor PD-1 on Antigen- Specific T-cells, increases the production of cytokines by tumor-infiltrating lymphocytes (TIL), and draining lymph nodes and augments anti-tumor activity via down-regulation of its target gene


What is known?

It has recently been shown that blocking PD-1 with antibodies one could make tumors shrink. This work, relating to Cancer immunotherapy, has been chosen as Science’s breakthrough of the year recently.


From Research Findings to Therapeutic opportunity

This suggests that NQO1, by decreasing the expression of its target gene, it may suppress the expression of PD-1. Thereby, it may (1) increase the production of cytokines by tumor-infiltrating lymphocytes (TIL), and draining lymph nodes; (2) augment antitumor activity of the immune system; & (3) inhibit metastatic cancer progression.

price-100

Thus, pharmacological formulations encompassing “NQO1 activators” may be used to inhibit the progression of tumors.


Details of the research findings:

Idea Proposed/Formulated (with experimental evidence) by: Dr L Boominathan Ph.D.

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

Amount: $100

Undisclosed information: How NQO1 suppresses the expression of PD-1 and augments anti-tumor immunity

# Research cooperation


References

Citation: Boominathan, L., Small molecule-based PD-1 pathway blockade for Human cancer therapy: NQO1 (NAD(P)H dehydrogenase [quinone] ) inhibits the expression of co-inhibitory receptor PD-1 on Antigen- Specific T-cells, increases the production of cytokines by tumor-infiltrating lymphocytes (TIL), and draining lymph nodes and augments anti-tumor activity via down-regulation of its target gene, 21/December/2016, 11.30 pm, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Web: http://genomediscovery.org or http://newbioideas.com

Courtesy: When you cite drop us a line at info@genomediscovery.org


Comments are closed.